Substance / Medication

Metipranolol

Overview

Active Ingredient
metipranolol
RxNorm CUI
10824

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Treatment of central serous chorioretinopathy with beta-blocker metipranolol.
Chrapek Oldrich, Jirkova Barbora, Kandrnal Vit et al. · Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub · 2015
PMID: 23549516RCT
Metipranolol blunts nitric oxide-induced lipid peroxidation and death of retinal photoreceptors: a comparison with other anti-glaucoma drugs.
Osborne Neville N, Wood John P M · Invest Ophthalmol Vis Sci · 2004
PMID: 15452090Observational
Inhibition of neutrophil migration and oxygen free radical release by metipranolol and timolol.
Djanani Angela, Kaneider Nicole C, Meierhofer Christian et al. · Pharmacology · 2003
PMID: 12837974Observational
Metipranolol attenuates lipid peroxidation in rat brain: a comparative study with other antiglaucoma drugs.
Melena José, Osborne Neville N · Graefes Arch Clin Exp Ophthalmol · 2003
PMID: 12898280Observational
The beta-adrenoceptor antagonists metipranolol and timolol are retinal neuroprotectants: comparison with betaxolol.
Wood J P M, Schmidt K-G, Melena J et al. · Exp Eye Res · 2003
PMID: 12634114Observational
Metipranolol promotes structure and function of retinal photoreceptors in the rd10 mouse model of human retinitis pigmentosa.
Kanan Yogita, Khan Mahmood, Lorenc Valeria E et al. · J Neurochem · 2019
PMID: 30315650PreclinicalFull text (PMC)
The beta-adrenergic receptor antagonist metipranolol blunts zinc-induced photoreceptor and RPE apoptosis.
Osborne Neville N, Wood John P M · Invest Ophthalmol Vis Sci · 2006
PMID: 16799065Preclinical

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Metipranolol (substance)
SNOMED CT
373446000
UMLS CUI
C0041030
RxNorm CUI
10824

Clinical Data

This intervention maps to 2 entities in the Ltrl knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.